← Back to Search

Dietary Supplement

Dairy Fat for Obesity

N/A
Waitlist Available
Led By Bruce Hammock, PhD
Research Sponsored by University of California, Davis
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Central obesity (waist circumference greater than 40 inches for men and 35 inches for women); fasting blood triglycerides greater than or equal to 150 mg/dL; plasma HDL cholesterol (Less than 40 mg/dL for men and less than 50 mg/dL for women); blood pressure greater than or equal to 130/85 mmHg; fasting glucose greater than or equal to 100 mg/dL
Two or more components of metabolic syndrome: Central obesity, fasting blood triglycerides, plasma HDL cholesterol, blood pressure, fasting glucose, or BMI equal to or greater than 30
Must not have
Cancer
Use of over-the-counter anti-obesity agents within the last 12 weeks
Timeline
Screening 3 weeks
Treatment Varies
Follow Up change from 0 hour up to 6 hours postprandial
Awards & highlights

Summary

This trial is studying the effects of dairy fat on postprandial inflammation in people with obesity or metabolic syndrome.

Who is the study for?
Adults aged 18-65 with metabolic syndrome or obesity, defined by specific criteria such as waist size, blood fat levels, and blood pressure. Excluded are pregnant women, heavy drinkers, those on certain medications or with gastrointestinal disorders, extreme obesity (BMI >40), recent significant weight changes or dietary shifts.Check my eligibility
What is being tested?
The study is testing how different types of fats affect inflammation in people with metabolic issues after eating a high-fat meal. It compares the effects of dairy fat rich in milk fat globule membrane (MFGM) to palm fat over six hours.See study design
What are the potential side effects?
Since this trial involves consumption of dietary fats rather than medication, side effects may include digestive discomfort or changes in energy levels. However, detailed potential side effects related to consuming these specific fats aren't provided.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
You have a large waist, high triglycerides, low HDL cholesterol, high blood pressure, or high blood sugar.
Select...
I have at least two symptoms of metabolic syndrome.
Select...
I am between 18 and 65 years old.

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:
Select...
I have been diagnosed with cancer.
Select...
I have not used over-the-counter weight loss drugs in the last 3 months.
Select...
I use anti-inflammatory pain medication every day.
Select...
I have lost or gained more than 10% of my weight in the last 6 months.
Select...
I have Type II diabetes.
Select...
My BMI is over 40.
Select...
I do not have any major liver or kidney diseases.
Select...
I have a gastrointestinal disorder such as Crohn's, colitis, or celiac disease.
Select...
I have an immune-related condition like autoimmune disease or asthma.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~change from 0 hour up to 6 hours postprandial
This trial's timeline: 3 weeks for screening, Varies for treatment, and change from 0 hour up to 6 hours postprandial for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Plasma inflammatory mediators
Secondary outcome measures
Tumor Markers
Plasma glucose
Plasma lipid profile
+2 more

Trial Design

4Treatment groups
Experimental Treatment
Active Control
Group I: Palm fat + MFGMExperimental Treatment1 Intervention
The amount of calories in the shake will be equivalent to 30% of each participant's calculated energy expenditure. The macronutrient composition of the shake as a percent of energy will be: 45% fat, 40% carbohydrate and 15% protein. The shake will contain palm fat, frozen fruit, glucose polymer, and BPC50, a dairy fraction rich in milk fat globule membrane proteins and phospholipids. Fifty percent of the shake's fat will be derived from BPC50.
Group II: Dairy fat + MFGMExperimental Treatment1 Intervention
The amount of calories in the shake will be equivalent to 30% of each participant's calculated energy expenditure. The macronutrient composition of the shake as a percent of energy will be: 45% fat, 40% carbohydrate and 15% protein. The shake will contain whipping cream, frozen fruit, glucose polymer, and BPC50, a dairy fraction rich in milk fat globule membrane proteins and phospholipids. Fifty percent of the shake's fat will be derived from BPC50.
Group III: Palm fatActive Control1 Intervention
The amount of calories in the shake will be equivalent to 30% of each participant's calculated energy expenditure. The macronutrient composition of the shake as a percent of energy will be: 45% fat, 40% carbohydrate and 15% protein. The shake will contain palm fat, frozen fruit, glucose polymer, and protein powder.
Group IV: Dairy fatActive Control1 Intervention
The amount of calories in the shake will be equivalent to 30% of each participant's calculated energy expenditure. The macronutrient composition of the shake as a percent of energy will be: 45% fat, 40% carbohydrate and 15% protein. The shake will contain whipping cream, frozen fruit, glucose polymer, and protein powder.

Research Highlights

Information in this section is not a recommendation. We encourage patients to speak with their healthcare team when evaluating any treatment decision.
Mechanism Of Action
Side Effect Profile
Prior Approvals
Other Research
Common treatments for Metabolic Syndrome include lifestyle modifications such as diet and exercise, medications to manage blood pressure, cholesterol, and blood sugar levels, and specific dietary interventions. The trial studying Dairy Fat Fractions Rich in Milk Fat Globule Membrane focuses on reducing postprandial inflammation, which is crucial because inflammation is a key component of Metabolic Syndrome. By targeting inflammation, these treatments can help reduce the risk of cardiovascular diseases and improve overall metabolic health in patients with Metabolic Syndrome.
Dairy attentuates oxidative and inflammatory stress in metabolic syndrome.Effects of low-fat or full-fat fermented and non-fermented dairy foods on selected cardiovascular biomarkers in overweight adults.

Find a Location

Who is running the clinical trial?

University of California, DavisLead Sponsor
919 Previous Clinical Trials
4,720,854 Total Patients Enrolled
12 Trials studying Metabolic Syndrome
634 Patients Enrolled for Metabolic Syndrome
Dairy Research InstituteOTHER
17 Previous Clinical Trials
973 Total Patients Enrolled
4 Trials studying Metabolic Syndrome
252 Patients Enrolled for Metabolic Syndrome
Bruce Hammock, PhDPrincipal InvestigatorUC Davis

Media Library

Dairy fat (Dietary Supplement) Clinical Trial Eligibility Overview. Trial Name: NCT01811329 — N/A
Metabolic Syndrome Clinical Trial 2023: Dairy fat Highlights & Side Effects. Trial Name: NCT01811329 — N/A
Dairy fat (Dietary Supplement) 2023 Treatment Timeline for Medical Study. Trial Name: NCT01811329 — N/A
Metabolic Syndrome Research Study Groups: Palm fat, Palm fat + MFGM, Dairy fat, Dairy fat + MFGM
~3 spots leftby Jul 2025